C4 Imaging, a medical device company, has announced the first patient implant with Sirius, the company’s novel positive-signal MRI Marker.
Sirius is used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant magnetic resonance (MR) imaging procedure.
The first implant was performed at The University of Texas MD Anderson Cancer Center (Houston, Texas) and was used during a procedure with IsoRay™ Medical’s Cesium-131 seeds.
C4 Imaging president and CEO Andrew Bright noted this first implant is a significant milestone.
"MR imaging of the implanted Sirius™ MRI Markers was successful and the clinical team were able to localize the implanted seeds. We were delighted to partner with IsoRay™ Medical for this first implant. IsoRay are leading innovators in the use of brachytherapy to treat prostate cancer, as well as many other tumors, and recognize the potential of MR imaging to optimize treatment quality and patient care," Bright added.